1. Introduction {#sec1}
===============

Evidence of the domestication of a handful of animal species, including pigs, can be traced back to early recorded human civilization ([@bib16], [@bib31]). Animal production plays important roles in the continued human evolution in both physical and mental health as well as social and economic viability ([@bib73], [@bib19]). Animal production, in providing meats, contributes greatly to social and economic activities and wellbeing ([@bib73], [@bib22]). Current world food animal production is represented by compound feed production at 980 million dry tons valued at about \$460 billion US per year with monogastric poultry and swine feeding accounting for 72% of the total production volume ([@bib1]). Feed cost typically accounts for about 70% of the operation expenses in intensive food animal production. China׳s compound feed production is at 183 million dry tons, accounting for about 18.7% of the world, market value, which is estimated at about \$170 billion US per year ([@bib1]). Current intensive food animal production practices are faced with challenges and obstacles to evolve the industry to be socially, economically and environmentally sustainable with an emerging one being the antimicrobial resistance concern ([@bib50], [@bib30]).

For the past several decades, antibiotics have been by far the most cost-effective way to maintain feed efficiency and health status in intensive animal production systems, including poultry and swine ([@bib12], [@bib51]). However, dietary supplementation of sub-therapeutic levels of feed antibiotics in animal production has now been recognized as the main determinant of antimicrobial resistance ([@bib14], [@bib24]). Antibiotic-resistant commensal and pathogenic bacteria can be directly spread to humans via retail meat products ([@bib36]), transferred into the environment after manure application ([@bib9]), and are further transmitted into ecosystems ([@bib43]). Antimicrobial resistance that originates from use of feed antibiotics in livestock industries contributes to the development of multidrug resistance "Superbugs" that are jeopardizing effective treatment of infectious diseases in human patients ([@bib30]), pets ([@bib82]), and wild birds ([@bib32]), becoming a major threat to global public health ([@bib87]).

On the other hand, use of sub-therapeutic levels of feed antibiotics neither eliminates food-borne pathogenic bacteria from food production animals ([@bib7], [@bib51]) nor detoxifies lipopolysaccharide (LPS) endotoxin ([@bib44], [@bib10]). These food animals׳ gut systems are a safe hideout and reservoir for the pathogenic bacteria ([@bib36], [@bib53]). Thus, alternative strategies need to be developed to replace feed antibiotics and to effectively detoxify pathogenic endotoxins and minimize pathogenic bacterial populations while maintaining and enhancing efficiency and health status of agricultural production food animals including poultry and swine.

2. History of sub-therapeutic levels of antibiotics as growth promoters {#sec2}
=======================================================================

Antibiotics are arguably the most successful form of chemotherapy discovered in the history of medicine ([@bib88]). The initial use of antibiotics as growth promoters in food animal production dates back to the "golden era" of antibiotic discovery during 1940׳s to 1960׳s ([@bib84], [@bib88]). The widespread use of sub-therapeutic levels of feed antibiotics primarily in monogastric food animal production has been practiced since the 1960׳s when the average cost of feed-grade antibiotics was dramatically reduced ([@bib12]). Mode of actions associated with the use of sub-therapeutic levels of feed antibiotics for improving feed efficiency and health status in food animals is still not completely clear. The classic mechanisms of feed antibiotics for improving feed efficiency include the control of bacterial over-growth, more essential luminal nutrients available for host growth, and stimulation of immunity ([@bib84], [@bib12], [@bib25]). Feed antibiotics are recently shown to increase gut microbial genes relating to energy production and conversion ([@bib51]). Thus, applications of sub-therapeutic levels of feed antibiotics are still regarded as the most cost-effective way to improve feed utilization efficiency and health status in monogastric food animal nutrition. An effective alternative strategy needs to be developed in order to replace feed antibiotics as growth promoters in monogastric food animal production.

Use of sub-therapeutic levels of feed antibiotics induces significant changes in the gut microbiota by reducing bacterial diversity ([@bib56], [@bib51]). Studies have demonstrated that failure to establish and maintain a normal gut microbiota would promote innate immune activation and may impair immune homeostasis ([@bib58], [@bib57], [@bib77]). Thus, young animals fed sub-therapeutic levels of feed antibiotics are susceptible to innate immune activation. Furthermore, feed antibiotics do not eliminate commensal and pathogenic bacteria, and this is largely due to the fact that bacteria develop antibiotic resistance genes ([@bib24]). For example, feed antibiotics increase commensal and pathogenic *Escherichia coli* populations in weanling pigs׳ gut ([@bib51]). Animals׳ gut is a main reservoir of pathogenic bacteria, which is the primary source of food-borne pathogens ([@bib36], [@bib53]). Thus, applications of sub-therapeutic levels of feed antibiotics as growth promoters do not disinfect pathogenic bacteria in animal production. There is an urgent need to develop a fundamentally new approach to prevent dysbiosis in swine production and minimize pathogenic bacterial impact on meat safety and public health concerns.

Use of sub-therapeutic levels of feed antibiotics is known to attenuate but does not fundamentally resolve the traditional challenges of post-weaning growth lag or check and the weaning-associated pig morbidity and mortality, which hampers the swine industry ([@bib83]). Scientifically, this is because feed antibiotics do not completely eliminate intestinal Gram-negative bacteria that produce and shed LPS endotoxin into the gut lumen ([@bib75], [@bib17], [@bib45]). Biologically, feed antibiotics do not detoxify the LPS endotoxin. Furthermore, intestinal apical alkaline phosphatase, being recognized as the primary endogenous LPS detoxification enzyme, is less effective with its less physiological optimal pH of 10.5 ([@bib20]), as well as its decreased maximal enzyme activity and enzyme affinity or enzyme efficiency in potentially detoxifying the LPS endotoxin in the weanling pig ([@bib46]), making weanling pigs susceptible to the development of endotoxemia.

It has now been demonstrated that LPS is effectively transported across the intestinal epithelial apical membrane via an endocytosis process in conjunction with long-chain fatty acid assembly into chylomicrons and makes its way into the systemic circulation ([@bib26], [@bib66]). Dr. Bruce Beutler was a recipient for the 2011 Nobel Prize in Physiology or Medicine for leading research in revealing that toll-like receptor 4 (TLR4) was the LPS receptor in the endotoxin-mediated inflammation via innate immunity ([@bib72]). Luminal and systemic circulating LPS endotoxin triggers gut mucosal local ([@bib56], [@bib68]), and systemic inflammation ([@bib42]) via innate immunity mediated by TLR4, enhancing gut permeability ([@bib76], [@bib48]), releasing pro-inflammatory cytokines into systemic circulation ([@bib42]), resulting in anorexia ([@bib37], [@bib6]), and causing sickness behavior and diminishing welfare in animals ([@bib39], [@bib13]). Hence, intestinal luminal LPS and systemic endotoxemia are largely responsible for monogastric food animal morbidity and mortality. Applications of sub-therapeutic levels of feed antibiotics as growth promoters do not detoxify LPS endotoxin and associated pro-inflammatory cytokine effects in major food production monogastric animals such as poultry and swine.

3. Antimicrobial resistance and conventional alternative strategies {#sec3}
===================================================================

Antimicrobial resistance has now become a major threat to global public health ([@bib87]). Antibiotic resistance genes existed before the "antibiotic era" ([@bib3]). All genes encode proteins that show resistance to antimicrobials and are referred to as resistome ([@bib88]). Development of antimicrobial resistance in swine production has been well documented to occur in two major distinctive types, including antibiotic-induced antibiotic resistance (e.g., [@bib3]) and heavy metal-specific (i.e., Cu and Zn, in particular) antimicrobial resistance ([@bib23]) due to feeding pharmacological levels of Cu (200 to 250 mg/kg) and Zn (2,000 to 3,000 mg/kg) as growth promoters ([@bib19]).

To address the antibiotic resistance concerns, European Union banned sub-therapeutic levels of feed antibiotics during 1997 to 1999, which actually led more therapeutic antibiotics uses in food animal production and deteriorated antibiotic resistance to therapeutic antibiotics ([@bib7]). The [@bib7] study support the view that a simple ban on sub-therapeutic levels of feed antibiotics as growth promoters will not fundamentally eliminate the antibiotic resistance concerns ([@bib51]). Therefore, a new effective approach to prevent dysbiosis and to detoxify LPS endotoxin needs to be developed in order to replace the sub-therapeutic levels of feed antibiotic and pharmacological levels of Cu and Zn uses in swine production and minimize the antimicrobial resistance threat to public health.

Development of alternative strategies in terms of nutritive and non-nutritive feed supplements and or additives to replace the sub-therapeutic levels of feed antibiotic in monogastric food animal production has been a hot topic of research for the past decade and this is reflected by a series of reviews of literature reports ([@bib81], [@bib67], [@bib48], [@bib34], [@bib19], [@bib69]). Current alternative strategies can be categorized into two groups, including the strategies that improve host animal growth and gut mucosal immunity and the strategies that directly or indirectly control pathogenic bacterial proliferation in the gut environment. Examples of the first category strategies include the use of rapidly digestible sugar supplements such as crystalline lactose and dry whey powder for optimal growth performances in weanling pigs ([@bib52], [@bib81], [@bib33]). Several strategies have been developed to directly improve gut mucosal growth and functions, including using sweeteners ([@bib79]), gut trophic crystalline amino acids and short peptides (e.g., [l]{.smallcaps}-glutamine) ([@bib89], [@bib85], [@bib19]), growth factors such as recombinant lactoferrin and epidermal growth factor ([@bib19]), as well as positive immunomodulatory compounds such as β-glucans ([@bib33]) and omega-3 polyunsaturated fatty acids ([@bib19]). A great deal of research efforts have been devoted to develop various prebiotic, i.e., non-viscous soluble fibers, and probiotic supplements to promote healthy gut microbiota and improve host weanling pig health and growth ([@bib67], [@bib18]). Examples of the second category strategies include the formulation of low-crude protein diets by using crystalline free amino acids to reduce pathogenic bacterial proliferation ([@bib49], [@bib4], [@bib27]), dietary supplementation of organic acids ([@bib41], [@bib65], [@bib19]) and dietary inclusion of pathogen-specific egg-white antibody proteins and spray-dried plasma proteins ([@bib54], [@bib81], [@bib67], [@bib19]). Although pharmacological levels of Cu and Zn are shown to be effective to promote pig growth, their dietary supplementations pose detrimental environmental concerns ([@bib19], [@bib34]). More recent work has provided evidence to show that pharmacological levels of Cu and Zn used concomitantly induce certain types of antibiotic resistance ([@bib8]).

The general key limitations associated with above reviewed alternative common strategies are that these strategies do not always and consistently prove to be effective under all tested conditions and nor do these strategies effectively disinfect pathogenic bacteria and or detoxify LPS endotoxin. It is essential to develop an effective strategy for detoxification of LPS endotoxin and resolve the gut health challenge facing the monogastric food animal production.

4. Metabolic endotoxemia and efficiency of nutrient utilization {#sec4}
===============================================================

Metabolic endotoxemia is defined as a two-to threefold increase in circulating endotoxin concentrations above normal detectable levels ([@bib38]). Normal blood circulating levels of endotoxin concentrations, when expressed as an endotoxin unit (EU), are 0.1 to 0.2 EU/mL plasma reported in rodents ([@bib26], [@bib38]) and humans ([@bib66]). Metabolic endotoxemia leads to low-grade systemic inflammation, as further manifested by increased serum levels of pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha (TNF-a) and enhanced gut permeability, causing accelerated translocation of endotoxin and resulting in a vicious cycle of endotoxemia ([@bib38]). In human nutrition and health, high-fat Western diets induced metabolic endotoxemia and contributed to the development of metabolic syndrome ([@bib26], [@bib66], [@bib38]). Paradoxically, metabolic endotoxemia is poorly defined in monogastric food animals for their nutrition and metabolic research especially under practical swine production conditions. Measurements of plasma concentrations of endotoxin are no longer a technical limitation and assay kits for this type of measurements are readily available from commercial sources.

Poor energy efficiency and low profit margin of swine production is known to be associated with very low efficiency of whole body total nitrogen, i.e., crude protein (CP), retention during the post-weaning pig growth and detrimental impacts on the environment in swine production ([@bib21]). Whole body efficiency of nitrogen utilization in swine declines dramatically from the suckling (83%) to the finishing phase (51%), and this is largely because gastrointestinal endogenous nitrogen and catabolic nitrogen losses are dramatically augmented due to genetic programming and changes in diets and sanitary conditions ([@bib21]). Efficiency of whole body nitrogen utilization is low during most of the post-weaning production growth in swine ([@bib19]). Systemic inflammation has been well documented to affect efficiency of nutrient utilization in monogastric food animals ([@bib42]). Gut luminal endotoxin and inflammation is inevitably, in part, responsible for the increased gastrointestinal endogenous nitrogen loss ([@bib21]), since endotoxemia leads to increases in visceral organ protein synthetic activities ([@bib63]). Systemic endotoxin is also demonstrated to dramatically increase muscle protein catabolism ([@bib64]). Majority of current literature reports regarding effects of endotoxin on swine nutrition and metabolism have been conducted with acute ([@bib86], [@bib15]) or chronic intraperitoneal injection (i.p.) of LPS models ([@bib62], [@bib40], [@bib74]). Nevertheless, it can be concluded that the presence of endotoxin partially accounts for the poor efficiency of nutrient utilization, low profit margin and some of the major environmental sustainable issues facing monogastric food animal of poultry and swine production. Thus, it is essential to develop effective and direct strategies for mitigation of the detrimental impact of enteric pathogenic bacterial toxins such as LPS endotoxin that are challenging the gut health in intensive monogastric food animal production.

5. Novel and disruptive biological strategies to improve monogastric food animal gut health {#sec5}
===========================================================================================

Novel and disruptive strategies have been effectively developed and used in intensive monogastric food animal nutrition and production including the dietary supplementations of purified trace mineral and vitamin supplements ([@bib60], [@bib61]), the use crystalline limiting essential and non-essential amino acids in formulating low-protein diets ([@bib27]), and the application of phytase technologies for resolving the concern of poor efficiency of phosphorus utilization ([@bib80], [@bib29], [@bib11]). It is apparent from the above discussions that novel strategies need to be developed to directly and effectively disrupt the key step or component from pathogenic bacteria that causes immunological and infectious responses to the host. It is rather challenging to completely disinfect and sterilize pathogenic bacteria without affecting commensal microflora in the gut environment such as the current practices of dietary supplementations of feed antibiotics, organic acids, and pharmacological levels of copper and zinc. Three potentially disruptive biological strategies may be further developed to specifically target at the major pathogenic bacterial endotoxin LPS, including regulation of the bacterial membrane polysaccharide biosynthesis pathway, lipolysis of the LPS lipid A moiety by unique lipases & esterases, and dephosphorylation of the LPS diphosphoryl lipid A moiety by alkaline phosphatases. These three potential strategies are further elaborated below.

Both Gram-negative and Gram-positive bacterial cell surfaces anchor a large number of polysaccharides and these polysaccharides play important roles in a wide variety of biological processes such as adhesion to biotic and abiotic substrata, motility, biofilm formation, cell--cell communication and immune system interaction and activation ([@bib35]). For example, polysaccharides represent a large core of the Gram-negative bacterial endotoxin LPS. Thus, understanding of regulation of the bacterial membrane polysaccharide biosynthesis pathway has been a major focus of molecular microbiology research to develop pharmacological strategies for combating bacterial immune activation and infections.

Pathogenic bacterial endotoxin LPS typically consist of two distinct structural features, including a hetropolysaccharide chain and a lipid A moiety. The lipid A moiety has been established as the main toxic determinant of LPS in mediating immune responses via TLR4 ([@bib2]). It has been well established that the presence of the three structural components in the lipid A moiety is essential for LPS to induce their toxic effects and these include both phosphate groups, the glucosamine disaccharide, and all the fatty acyl chains especially the 2'-lauroyl and 3'-myristoyl acyloxy residues ([@bib2]). Detoxification of bacterial LPS via deacylation and lipolysis of the lipid A moiety through leukocyte, liver and kidney acyloxyacyl hydrolase (AOAH), an endogenous lipase, was reported ([@bib59], [@bib78]). [@bib2] demonstrated that some of the screened microbial lipases and esterases were considerably more efficacious than mammalian pancreatic and hepatic lipases and esterases in hydrolytically releasing laurate and myristate from LPS. These results have two important gut health implications. Firstly, the endogenous lipases and esterases in animals are likely limited in their efficacy in detoxification of bacterial LPS via deacylation and lipolysis of the lipid A moiety. Secondly, development of novel and efficacious lipases and esterases as exogenous enzyme supplements may be one of the alternative disruptive strategies for detoxification of enteric endotoxin LPS in protecting gut health of food animals.

Intestinal alkaline phosphatase (IAP) is one of the most abundant brush border membrane-bound proteins ([@bib55], [@bib20]). Its classic physiological functions include intestinal absorption of lipids, regulation of duodenal secretions and pH, detoxification of bacterial endotoxins, and regulation of the transmucosal passage of bacteria ([@bib47]). The most important physiological function of alkaline phosphatases is their unique biochemical property of detoxification of the endotoxin LPS via dephosphorylation. [@bib55] were the first to propose the potential role of alkaline phosphatases in dephosphorylation of potential toxins. [@bib70], [@bib71] were the first to demonstrate that alkaline phosphatases were responsible for detoxification of the endotoxin LPS via dephosphorylation *in vivo* studies with rats. [@bib5] and [@bib44] subsequently showed that the removal of phosphate from the lipid A moiety in LPS was the mechanism of endotoxin detoxification by alkaline phosphatases. Various physiological and dietary factors are shown to affect the expression and functionality of IAP in animals ([@bib47]). Inadequate supply of enteral nutrients resulted in abnormal expression and functionality of IAP, which was demonstrated in rodent models ([@bib28]). Inflammation and pro-inflammatory cytokines inhibited intestinal alkaline phosphatase expression ([@bib47]). Intestinal alkaline phosphatases prevented metabolic endotoxemia, low-grade inflammation and metabolic syndrome in mice fed high-fat diets ([@bib38]). Our previous studies shown that early weaning in piglets dampened the maximal enzyme activity and the digestive capacity of the IAP by down-regulation of this gene at the transcriptional, translational and post-translational levels with considerable decreases in the apical IAP abundance and affinity in the proximal jejunum ([@bib46]). Therefore, development of novel and efficacious alkaline phosphatases as exogenous enzyme supplements may be another alternative disruptive strategy for detoxification of enteric endotoxin LPS in protecting gut health of food animals.

6. Conclusions {#sec6}
==============

Wide use of feed antibiotics as growth promoters in monogastric food animal production in the past six decades has contributed to the development of antimicrobial resistance, threatening to the world public health. Efficacy of currently available alternative feed additives in replacing feed antibiotics to maintain productivity and gut health is inconsistent dependent upon experimental conditions. Disruptive biological strategies such as novel lipases & esterases and alkaline phosphatases as exogenous feed enzymes need to be developed in replacement of feed antibiotic growth promoters to directly and effectively detoxify the endotoxin LPS and to maintain gut health and performances in monogastric food animals.
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